Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Merck's Keytruda Approved as Monotherapy for Lung Cancer in China

publication date: Oct 3, 2019

Merck/MSD announced China approval of Keytruda, the company's anti-PD-1 immunotherapy, as a first-line monotherapy to treat advanced or metastatic non-small cell lung cancer without chemotherapy. Previously, China's NMPA approved Keytruda as a first line NSCLC treatment together with chemotherapy, and in 2018, it was approved in China as a second-line treatment for metastatic myeloma. Merck said Keytruda caused a statistically significant improvement in overall survival compared to chemotherapy in a China extension of a global NSCLC trial. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.